Drug intelligence / Profile preview

SOL-005

Development stage: Preclinical
Lead developer: Soley Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

SOL-005 is an orally bioavailable small molecule therapeutic currently in preclinical development for the treatment of various oncology indications. Developed by Soley Therapeutics, the compound was identified using the company's proprietary AI-driven drug discovery platform, which integrates machine learning with biological datasets to identify novel therapeutic candidates. As of 2024, the specific molecular target and mechanism of action for SOL-005 remain undisclosed by the sponsor, though it is positioned as a targeted therapy within their cancer pipeline.

Beyond the preview

Go deeper on SOL-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOL-005.

Explore the full profile